CD93 and neoplasm: We further examined if the decreased tumoral B cell infiltrate was attributable to a specific B cell subset and found that PKD inhibition primarily decreased the frequency of follicular (CD19+CD93-CD21LoIgDHi) B cells within the tumor (Supplementary Figure 10A).